Why the study?
Direct oral anticoagulants require different reversal strategies than warfarin, and anticoagulation reversal in acute intracerebral hemorrhage is an evolving field.
This article reviews the most common direct oral anticoagulant medications, available reversal strategies, and current guidelines for managing acute intracranial hemorrhage.
May support guideline-based reversal decisions in acute ICH; leaves open head-to-head studies of DOAC antidotes.
Intracerebral hemorrhage is a major source of morbidity and mortality, accounting for 10% of all strokes. Oral anticoagulation therapy, while necessary to prevent thromboembolic complications, increases the risk of intracerebral hemorrhage and can potentially worsen bleeding in cases of acute hemorrhage. Before the introduction of direct oral anticoagulant agents in 2010, warfarin was the only option for oral anticoagulation. These new agents have an improved safety profile compared with warfarin but require different reversal strategies. Anticoagulation reversal in the setting of acute intracerebral hemorrhage is an evolving field. This article covers the most common direct oral anticoagulant medications, various available anticoagulant reversal strategies, and the latest guidelines for anticoagulation reversal in patients with acute intracranial hemorrhage.
No takes yet. Share an insight, caveat, or question.
Nestor et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: